Cell News and Research

RSS

Biodegradable scaffold with magnesium and glutamine accelerates bone regrowth

For most broken bones, bone cells regrow on their own while patients wear a cast or brace to keep the injury steady.

9 Sep 2025

Dengue infection leaves lasting genetic imprint on immunity

Just as a computer's operating system can be rewritten after a major update, dengue infection can 're-programme' the body's immune system, leaving a long-lasting genetic imprint that influences how people respond to future infections-an effect not seen with vaccination.

9 Sep 2025

Cancer cells found to use ketones as alternate fuel for growth

When it comes to their survival, cancer cells have a host of backup plans.

8 Sep 2025

Scientists identify key protein driving severe flu in older people

Scientists have discovered why older people are more likely to suffer severely from the flu, and can now use their findings to address this risk.

8 Sep 2025

Folic acid fortification linked to tripled gestational diabetes rates in Australian study

Researchers in Australia found that after mandatory folic acid fortification, gestational diabetes rates tripled, maternal folate levels rose sharply, and placental hormone profiles shifted. The study links folate excess to increased GDM risk, highlighting the need to re-evaluate supplementation policies.

8 Sep 2025

Mushrooms deliver nutrition medicine and sustainability solutions in one package

This Food Science & Nutrition review highlights mushrooms as nutrient-rich functional foods packed with bioactive compounds that support human health. It explores their therapeutic, industrial, and environmental applications, from disease prevention and drug discovery to bioremediation and bioenergy.

8 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Study could pave the way for simple blood test to diagnose Alzheimer's disease

In a landmark study of Hispanic and Latino adults, researchers at University of California San Diego School of Medicine have identified a link between self-reported cognitive decline and blood-based biomarkers, which could pave the way for a simple blood test to help diagnose Alzheimer's disease and related dementias.

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

New hydrogel may help alleviate negative impacts of menopause

A new hydrogel applied directly to vaginal tissues may help alleviate the negative impacts of menopause, according to a new study from scientists at the University of California San Diego.

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

8 Sep 2025

Video-assisted thoracoscopic surgery provides improved overall survival compared to open lobectomy

Patients who underwent video-assisted thoracoscopic surgery (VATS) compared to open lobectomy had a significantly improved overall survival rate, according to a meta-analysis presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Can gaming strengthen the brain’s attention pathways?

Research reveals structural brain differences in action gamers, with greater cortical thickness and connectivity in regions vital for visuospatial processing.

8 Sep 2025

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan’s Drug Regulatory Authority of Pakistan (DRAP).

From BioDlink 8 Sep 2025

Axxam and B'SYS partner to expand access to validated ion channel cell lines for high-throughput electrophysiology

Axxam S.p.A., a premier provider of integrated early drug discovery services, and B'SYS GmbH, a specialist in ion channel biology, are pleased to announce a strategic collaboration focused on enabling access to validated ion channel cell lines for hit and lead identification through high-throughput electrophysiological screening.

From Axxam S.p.A 8 Sep 2025

New drug candidate STF 1623 activates innate immunity in solid tumors

Cancer immunotherapy, which primes the body's immune system to fight off tumors, has historically focused on harnessing T cells' natural ability to recognize and attack cancer cells.

5 Sep 2025

Cell News and Research

Biodegradable scaffold with magnesium and glutamine accelerates bone regrowth

Dengue infection leaves lasting genetic imprint on immunity

Cancer cells found to use ketones as alternate fuel for growth

Scientists identify key protein driving severe flu in older people

Folic acid fortification linked to tripled gestational diabetes rates in Australian study

Mushrooms deliver nutrition medicine and sustainability solutions in one package

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

Study could pave the way for simple blood test to diagnose Alzheimer's disease

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

New hydrogel may help alleviate negative impacts of menopause

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Video-assisted thoracoscopic surgery provides improved overall survival compared to open lobectomy

Can gaming strengthen the brain’s attention pathways?

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

Axxam and B'SYS partner to expand access to validated ion channel cell lines for high-throughput electrophysiology

New drug candidate STF 1623 activates innate immunity in solid tumors

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo